search

Active clinical trials for "Rift Valley Fever"

Results 1-8 of 8

Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine

Rift Valley Fever

This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine

Recruiting30 enrollment criteria

RVF and Other Emerging Infectious Diseases in East and Central Africa

Rift Valley FeverHemorrhagic Fevers1 more

Rift Valley fever (RVF), a disease transmitted from livestock (cattle, sheep, goats, camels) to humans more commonly occurs in the East and Central Africa (ECA) regions where more than 15 major epidemics affecting more than one country have been reported over the past 50 years. Within the region, there are specific areas, referred to as hotspots, which support RVF virus maintenance via low-level virus circulation between animals, humans, and mosquitoes. Most outbreaks originate from these hotspots. Our goal is to conduct studies in RVF hotspots in four ECA countries, Kenya, Uganda, Tanzania, and Democratic Republic of Congo (DRC) to determine the burden of RVF disease among humans, wildlife and livestock during inter-epidemic periods (IEPs) and discover circulation of undetected infectious diseases. This information is important for use in developing an early warning system and possibly a vaccination strategy. The study will take place in Uganda, Kenya, Tanzania and Democratic Republic of Congo

Recruiting11 enrollment criteria

Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)

Rift Valley Fever

Phase I open label, non-randomised dose escalation study on healthy UK volunteers aged from 18 to 50 years to assess the safety and immunogenicity of ChAdOx1 RVF

Completed39 enrollment criteria

Safety and Immunogenicity Study of Rift Valley Fever Vaccine

Rift Valley Fever

This study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine

Completed19 enrollment criteria

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

Rift Valley Fever

This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the vaccine is stable or if the virus used to make the vaccine changes into a different form once injected into the body. Twenty healthy volunteers (18-50 years old) will be vaccinated with a single dose of undiluted RVF MP-12, injected into a muscle.

Completed30 enrollment criteria

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults

RVFRift Valley Fever

Randomised, single blind, placebo - controlled, dose-escalation, phase I clinical trial recruiting healthy adults aged 18-50 years

Completed34 enrollment criteria

Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

Rift Valley Fever

This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults

Completed16 enrollment criteria

Rift Valley Fever in Kenya

Rift Valley Fever

The purpose of this study is to find out how, why, and when Rift Valley Fever (RVF) spreads. Participants will be 250 adults and children, aged 1 year and older, from the Ijara District, Kenya. They will be given a questionnaire, undergo a medical examination that includes an eye exam, and have a 1-teaspoon sample of blood taken from a vein. Participation will take about 3 hours.

Completed8 enrollment criteria
1

Need Help? Contact our team!


We'll reach out to this number within 24 hrs